Deutsche Biotech Innovativ AG Logo

Deutsche Biotech Innovativ AG

Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.

DBI | F

Overview

Corporate Details

ISIN(s):
DE000A0Z25L1
LEI:
391200BIDNL2ZOKI1M61
Country:
Germany
Address:
Neuendorfstraße 15a, 16761 Hennigsdorf
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Deutsche Biotech Innovativ AG is a biotechnology company focused on the research and clinical development of therapeutic solutions for serious diseases with high unmet medical needs. The company leverages an innovative approach centered on blood biomarkers to identify and develop its drug candidates. Its portfolio includes Adrecizumab, an antibody-based therapy that has undergone clinical trials for the treatment of septic shock. DBI's strategy combines the development of both therapeutics and diagnostic biomarkers to address therapeutic challenges.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 00:00
Annual / Quarterly Financial Statement
Datum:29.09.2025
German 31.8 KB
2024-10-07 00:00
Annual Report
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 28.4 KB
2023-12-20 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 27.5 KB
2023-09-20 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 15.1 KB
2022-11-07 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 19.0 KB
2022-07-19 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 29.0 KB
2022-04-21 10:27
Regulatory News Service
Deutsche Biotech Innovativ AG: Paul-Ehrlich Institut-(PEI)-Zulassung fur eine d…
German 33.0 KB
2021-09-03 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 28.3 KB
2021-08-30 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 14.6 KB
2021-02-04 20:01
Board/Management Information
Deutsche Biotech Innovativ AG: Veranderungen in Vorstand und Aufsichtsrat
German 5.4 KB
2020-12-14 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
German 14.8 KB
2020-09-16 06:30
Earnings Release
Deutsche Biotech Innovativ AG: * Positive Ergebnisse der Phase-II-Studie Adreno…
German 6.5 KB
2020-08-25 10:58
Earnings Release
Deutsche Biotech Innovativ AG: Barrier function of blood vessels as therapeutic…
English 7.5 KB
2020-08-19 14:00
Major Shareholding Notification
Deutsche Biotech Innovativ AG: Further step towards a strong capital market ori…
English 7.6 KB
2020-08-19 09:15
Regulatory News Service
Deutsche Biotech Innovativ AG: Erste Investition in das Biomarker-Unternehmen S…
German 7.6 KB

Automate Your Workflow. Get a real-time feed of all Deutsche Biotech Innovativ AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Deutsche Biotech Innovativ AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Deutsche Biotech Innovativ AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.